WO2016186521A1 - Composition de stabilisation d'hémolyse - Google Patents

Composition de stabilisation d'hémolyse Download PDF

Info

Publication number
WO2016186521A1
WO2016186521A1 PCT/NZ2016/050077 NZ2016050077W WO2016186521A1 WO 2016186521 A1 WO2016186521 A1 WO 2016186521A1 NZ 2016050077 W NZ2016050077 W NZ 2016050077W WO 2016186521 A1 WO2016186521 A1 WO 2016186521A1
Authority
WO
WIPO (PCT)
Prior art keywords
haemolysis
stabilising
agent
approximately
haemoglobin
Prior art date
Application number
PCT/NZ2016/050077
Other languages
English (en)
Inventor
Maurice Cedric OWEN
Original Assignee
Canterbury Scientific Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canterbury Scientific Limited filed Critical Canterbury Scientific Limited
Publication of WO2016186521A1 publication Critical patent/WO2016186521A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells

Definitions

  • haemolysis stabilising compositions and methods of use. More specifically, haemolysis stabilising compositions are described for use in the medical industry for the analysis of blood samples from patients.
  • the compositions contain a combination of agents that provide various advantages.
  • Haemoglobin is the red blood protein that transports oxygen from the lungs to the tissues. It is the major component of the red blood cell (or erthyrocyte).
  • haemoglobins arise from the non-enzymatic attachment of glucose to haemoglobin. Because the life of a red cell averages some 120 days, the extent of haemoglobin glycation can be used as an indication of the average blood glucose level over the previous 2 -3 months and is thus useful as an indicator of diabetic control and as a diagnostic assay for diabetes.
  • haemoglobin A molecule of haemoglobin is made up of 4 protein chains. In the predominant adult form there are 2 alpha chains and 2 beta chains, usually denoted as ⁇ 2 ⁇ 2 - Glucose will react and bond to certain positively charged chemical groups on the haemoglobin. These are located at the start (N-terminal end) of each of the a and ⁇ chains and on some amino acid side chains within the protein such as the ⁇ -amino group of certain lysine residues.
  • Glycated haemoglobin is defined as haemoglobin with glucose bound to any of these potential sites.
  • HbAlc is a subset of glycated haemoglobins. It is defined as haemoglobin with glucose bound at the beginning (N-terminal) of the ⁇ -chain. The total glycated haemoglobin will include HbAlc plus all the other haemoglobins that have glucose bound to lysine side chains and/or to the N-terminal of the ct- chain.
  • HbAlc proceeds via a Schiff base adduct, or aldimine, (shown in step 1 above) followed by the Amadori rearrangement to form the stable ketoamine, HbAlc (shown in step 2 above). Glycation may occur on the Ale binding site (valine- 1 on the beta chain) and other non-Ale sites (valine- 1 on the alpha chain or lysine amino acid residues).
  • the aldimine intermediate is often referred to as labile HbAlc and the rate of its conversion to the ketoamine is some 60 times slower than the reverse dissociation with release of the glucose.
  • HbAlc is especially useful in insulin-dependent diabetic patients where blood glucose levels fluctuate widely and where the instantaneous blood glucose does not reflect the averaged situation.
  • the formation of HbAlc occurs slowly and continuously during the 120-day lifetime of the red cell.
  • the measurement of HbAlc is useful to physicians as a long-term indicator of blood glucose concentration and thus as a measure of the degree of control or self-management by the diabetic patient.
  • HbAlc The normal range for HbAlc is less than 5.8% of total haemoglobin, or in the IFCC units, less than about 40 mmol HbAlc/mol Hb.
  • HbAlc levels above 7.5% (or 58 mmol/mol) represent poor diabetic control, whereas values between 6.5% and 7.0% (48-53 mmol/mol) are indicative of good control.
  • a level of less than 5.8% (40mmol/mol) virtually excludes diabetes, with 41-49 mmol/mol indicative of abnormal glucose tolerance and greater than 50 mmol/mol supportive of the diagnosis of diabetes.
  • HbAlc is increasingly used as the diagnostic test of choice for diabetes.
  • blood samples are collected, usually by venipuncture, from the subject and sent to the analytical laboratory for analysis (such as on a Tosoh Bioscience G7 or G8 HPLC analytical instrument).
  • the result is usually delayed and is available to the doctor or nurse in 1 -2 days.
  • there is an added cost in transporting the blood samples which are kept chilled to prevent degradation of the HblAc by conversion of haemoglobin to met-Hb when a heme iron is oxidised from the ferrous state (Fe2+) to the ferric state (Fe3+) with a resulting colour change from bright red to dark brown, or oxidation of the protein thiol group.
  • This degradation may lead to inaccurate blood test results for HblAc due to the presence of an extra peak on some analytical instruments confounding the normal (desired) glycated Ale peak.
  • the blood sample is taken from the subject, and immediately analysed on a point of care analytical instrument.
  • the result is available to the doctor or nurse within a few minutes.
  • the blood sample is from a finger prick or puncture, as used in a blood glucose test, and as such is less traumatic than a venipuncture. Also the blood sampling does not require a nurse with specific training in blood venesection.
  • haemolysis stabilising composition and methods of use will become apparent from the ensuing description that is given by way of example only.
  • Haemoglobin is inherently unstable and will readily oxidise or degrade if exposed to temperatures above 37 °C in diluted form for any length time.
  • haemolysis stabilising compositions comprising at least one chelating agent, at least one pH buffering agent and at least one anticoagulant that contributes to stabilising the haemoglobin.
  • a haemolysis stabilising composition comprising:
  • haemolysis stabilising effective amount of at least one haemoglobin stabilising agent f) a haemolysis stabilising effective amount of at least one haemoglobin stabilising agent.
  • a haemolysis stabilising composition comprising: a) approximately 0.001 to 0.05% w/v of at least one red blood cell membrane solubilisation agent; b) approximately 0.01 to 0.10% w/v of at least one chelating agent;
  • a haemolysis stabilising solution comprising:
  • a haemolysis stabilising composition comprising:
  • haemolysis stabilisation composition releases and stabilises the cellular haemoglobins, comprising HblAc, to achieve an extracellular haemoglobin to HbAlc ratio that is at least 95 % of the haemoglobin to HbAlc ratio of freshly collected red blood cells.
  • a method of determining the HbAlc content in a blood sample from a patient comprising the steps of:
  • step (b) collecting the whole blood sample from the patient and transferring it into the receptacle of the whole blood sample container from step (a);
  • step (c) mixing the collected whole blood sample from step (b) above with the haemolysis stabilising composition in the receptacle;
  • step (d) loading the mixture from step (c) above on an analytical instrument to measure the HbAlc level.
  • a blood sample container comprising:
  • advantages of the composition and methods of use described herein may comprise: ⁇ Improved stability of haemoglobin during transportation at usual ambient temperatures so that the analysed sample gives the same result as if fresh; and
  • Figure 1 is a graph illustrating the relationship between HblAc levels (% of total haemoglobin) over time (hours) at a temperature of 20 to 25 °C.
  • haemolysis stabilising compositions and methods of use comprising at least one chelating agent, at least one pH buffering agent and at least one anticoagulant.
  • This combination of ingredients confers a haemolysis stabilisation effect with the advantages of improved stabilisation of haemoglobin and HbAlc such that it can tolerate ambient temperatures during transportation.
  • haemolysis stabilisation composition prepares the whole blood sample for direct analysis on the analytical instrument without further processing. Further the ratio of the different constituent haemoglobins remains substantially unchanged relative to the haemoglobin levels in a freshly collected sample. In this way, the HbAlc level obtained is the same as if the sample were tested with freshly collected blood.
  • the term 'about' or 'approximately' and grammatical variations thereof mean a quantity, level, degree, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% to a reference quantity, level, degree, value, number, frequency, percentage, dimension, size, amount, weight or length.
  • substantially' or grammatical variations thereof refers to at least about 50%, for example 75%, 85%, 95% or 98%.
  • the term 'comprise' and grammatical variations thereof shall have an inclusive meaning - i.e. that it will be taken to mean an inclusion of not only the listed components it directly references, but also other non-specified components or elements. This rationale will also be used when the term 'comprised' or 'comprising' is used in relation to one or more steps in a method or process.
  • 'haemolysis stabilising composition broadly relates to a composition that has a stabilising effect on the total haemoglobins that are liberated from the red blood cells.
  • 'Stabilising' as used here refers to inhibiting further haemoglobin degradation so as to limit its physical or chemical change.
  • HbAlc' refers to the subset of glycated haemoglobins with glucose bound at the beginning (N- terminal) of the ⁇ -chain.
  • the total glycated haemoglobin will include HbAlc plus all the other haemoglobins that have glucose bound to lysine side chains and/or to the N-terminal of the a-chain.
  • HbAlc is used as a measure of the degree of control or self-management of blood glucose by the patient and therefore as a indicator of diabetic control or as a diagnostic test for diabetes.
  • haemolysis stabilising effective amount is intended to qualify the amount of composition that will inhibit further haemoglobin degradation by stabilising the structure of haemoglobin and glycated haemoglobins (HbAlc).
  • red blood cell' refers to erythrocytes which are the most common blood cell, the contents of which is rich in haemoglobin and delivers oxygen to the body tissues.
  • red blood cell membrane solubilisation agent' refers to a chemical, such as a detergent, capable of solubilising the cell wall of a red blood cell to liberate the internal contents of the red blood cell (such as haemoglobin) into solution.
  • 'chelating agent' refers to a substance whose molecules can form multi-dentate ligands to single metal ions, such as calcium or magnesium ions in the blood.
  • 'methaemoglobin heme binding agent' refers to an agent capable of converting the heme iron from the ferric state (Fe 3+ ) to the ferrous state (Fe 2+ ) with a resulting colour change from dark brown to bright red .
  • 'pH buffering agent' refers to a substance which is either a weak acid or base capable of maintaining the pH of a solution near a chosen value after the addition of a further acid or base to the solution.
  • anticoagulant' refers to a substance, which prevents the clotting (or coagulation) of blood which occurs within 10 to 20 minutes of exposure to ambient temperatures, for example, sodium citrate dihydrate forms citrate ions in solution which chelates calcium ions in the blood by forming calcium citrate complexes and thereby disrupting the blood clotting mechanism.
  • 'haemoglobin stabilisation agent' refers to agents such as sodium chloride capable of forming salt bridges between the two alpha and the two beta chains of the haemoglobin protein molecule.
  • the term 'analytical instrument' refers to a machine capable of determining the levels of HbAlc in a blood sample without further preparation of the blood samples after collection, such as a high performance liquid chromatograph (HPLC), such as a Tosoh Bioscience G7 or G8 analytical instrument, or the like.
  • HPLC high performance liquid chromatograph
  • a haemolysis stabilising composition comprising:
  • haemolysis stabilising effective amount of at least one haemoglobin stabilising agent f) a haemolysis stabilising effective amount of at least one haemoglobin stabilising agent.
  • the haemolysis stabilising composition stabilises the level of haemoglobin (including HblAc) after whole blood sample collection. That is after approximately 1, or 2, or 3, or 4, or 5 or more days, or after approximately 20, or 30, or 40, or 50, or 60, or 70, or 80, or 90, or 100, or 110, or 120 hours or more.
  • haemoglobin including HblAc
  • the container containing the whole blood sample in the haemolysis stabilising composition is able to be loaded directly onto the analytical instrument (TOSOH G7/G8) without further preparation.
  • the composition may release and stabilise the cellular haemoglobins, comprising HblAc, to achieve an extracellular haemoglobin to HbAlc ratio that is at least 85%, or 90 %, or 95 %, or 99 % of the haemoglobin to HbAlc ratio of freshly collected red blood cells.
  • the composition may decrease the number of microbes sufficient to substantially the same levels as present in a fresh blood sample.
  • the composition may however be tailored to provide a lesser or greater stabilisation as desired by varying the concentration of the key active agents.
  • the pH of the composition may be between approximately 6.5, or 6.6, or 6.7, or 6.8, or 6.9, or 7.0, or 7.1, or 7.2, or 7.3, or 7.4, or 7.5, or 7.6, or 7.7, or 7.8 as measured at 25 °C.
  • the variation in pH may depend on the amount of pH buffering agent used such as the ratio of disodium hydrogen phosphate dihydrate to potassium dihydrogen phosphate anhydrous. The inventor has found that this pH range provides the advantage of effective haemolysis stabilisation by mimicking the natural blood pH range.
  • the pH is in the approximate range 6.5 to 7.45 and is 7.30.
  • the osmolality of the composition may be between approximately 59, or 60, or 61, or 62, or 63, or 64 mOsmol/kg. In one embodiment the osmolality is in the approximate range 60 to 80 mOsmol/kg and is 62. The inventor has found that in this osmolality range provides the advantage of effective haemolysis without compromising the stability of haemoglobin.
  • the red blood cell membrane solubilisation agent is an anionic detergent selected from the group consisting of: tritors X-100, DDM, digitorsirs, tween 20, tween 80. In one embodiment the anionic detergent may be triton X-100, or the like.
  • the red blood cell membrane solubilisation agent is approximately present in an amount 0.001, or 0.002, or 0.003, or 0.005, or 0.008, or 0.01, or 0.02, or 0.03, or 0.04, or 0.05 % w/v. In one embodiment the red blood cell membrane solubilisation agent is present in an amount between approximately 0.008 to 0.01 % w/v of the total composition.
  • the at least one chelating agent may be one or more members selected from the group comprising: EDTA (ethylenediaminetetraacetic acid), NTA (nitrilotriacetic acid), EDDA (ethylenediaminediacetic acid), CyDTA (trans- l,2-Diaminocyclohexane-N,N,N',N'-tetraacetic acid monohydrate), DPTA-OH (1,3-Diamino- 2-hydroxypropane ⁇ , ⁇ , ⁇ ', ⁇ '-tetraacetic acid), DTPA (Diethylenetriamine-N,N,N',N",N"-pentaacetic acid), EDDP (Ethylenediamine-N,N'-dipropionic acid, dihydrochloride), EDDPO [Ethylenediamine-N, N'- bis(methylenephosphonic acid), hemihydrate], EGTA [Ethyleneglycol-bis-( beta -amino-ethylether
  • Hexamethylenediamine-N,N,N',N'-tetraacetic acid HIDA [N-(2-Hydroxyethyl) iminodiacetic acid], IDA (Iminodiacetic acid), NTP (Nitrilotripropionic acid), NTPO [Nitrilotris (methylenephosphonic acid), trisodium salt], TTHA (Triethylenetetramine- ⁇ , ⁇ , ⁇ ', ⁇ '', ⁇ '", N"'-hexaacetic acid), etc., alpha -, beta -, gamma -CD (cyclodextrin), or these CD modified with polymer.
  • a preferred chelating agent is EDTA.
  • the EDTA can be a mixture of EDTA tetrasodium dihydrate and EDTA dipotassium dihydrate present at an amount of 0.01, or 0.02, or 0.03, or 0.04, or 0.05, or 0.06, or 0.07, or 0.08, or 0.09 or 0.1 % w/v and between 0.05 to 0.0423 % w/v of the total composition and the EDTA tetrasodium dihydrate is present at an amount 0.0285 % of the total composition and the EDTA dipotassium dihydrate is present at an amount of 0.0215 % w/v of the total composition.
  • EDTA can also function as an anticoagulant agent as well as a chelating agent. The dual functionality of components can decrease the complexity of the haemolysis stabilising solution.
  • the methaemoglobin binding agent may be sodium azide.
  • the methaemoglobin binding agent may be in an amount 0.01, or 0.02, or 0.03, or 0.04, or 0.05, or 0.06, or 0.07, or 0.08, or 0.09 % w/v of the total composition.
  • the methaemoglobin binding agent may be present in an approximate range 0.0336 to 0.045 % w/v of the total composition.
  • the oxy-haemoglobin form may be
  • the at least one pH buffering agent may be either an acid or base capable of maintaining the pH of the haemolysis stabilising composition when in solution near a chosen value after the addition of a further acid or base to the solution.
  • the pH buffering agent may be a mixture of disodium hydrogen phosphate dihydrate and potassium dihydrogen phosphate anhydrous.
  • the pH buffering agent may be present in a total amount of approximately 0.005, or 0.01, or 0.02, or 0.03, or 0.04 or 0.05 % w/v of the total composition. In one embodiment the pH buffering agent may be present in an approximate range 0.032 to 0.038 % w/v of the composition.
  • the disodium hydrogen phosphate dihydrate may be present in an amount 0.0285 % w/v of the total composition and the potassium dihydrogen phosphate anhydrous is present in an amount of approximately 0.0095 % w/v of the total composition.
  • the at least one anticoagulant may be tri-sodium citrate dihydrate.
  • the at least one anticoagulant may be present in an amount of approximately 0.05, or 0.10, or 0.15 % w/v of the total composition. In one embodiment the at least one anticoagulant may be present in an amount 0.05 to 0.10 % w/v of the total composition. For example, the at least one anticoagulant may be present in an amount 0.098 % w/v of the total composition.
  • Citrate ions in solution also provide a dual function as a haemoglobin stabilising agent.
  • the haemoglobin stabilisation agent may be a salt capable of making the haemolysis stabilising composition to have ions for salt bridges that are formed between the respective a and ⁇ globin chains.
  • the salt may be sodium chloride and/or potassium chloride.
  • the salt may be present in an amount of approximately 0.05, or 0.10, or 0.15, or 0.20 % w/v of the total composition. In one embodiment, the haemoglobin stabilising agent is present in an amount 0.09 to 0.102 % w/v of the total composition.
  • potassium chloride present in an amount of approximately 0.0027 % w/v of the total composition.
  • the haemolysis stabilising composition also comprises an antimicrobial agent capable of killing microbes in the blood sample such as bacteria, fungi or viruses.
  • the antimicrobial agent may be sodium azide.
  • the sodium azide is present in an amount of approximately 0.02 to 0.04 % w/v of the total composition and in one embodiment is present in an amount 0.0336 % w/v of the total composition.
  • the antimicrobial agent may be effective in killing microbes in a 3, or 3.5, or 4, or 4.5, or 5-log reduction.
  • the antimicrobial agent also modifies methaemoglobin to a form suitable for analytical purposes. So it has a dual function in the haemolysis stabilising composition.
  • a haemolysis stabilising composition comprising:
  • the inventor has un-expectantly found that these concentration ranges provides the advantage of effective haemolysis stabilisation.
  • a haemolysis stabilising solution comprising:
  • the solution should be sterile in order to prevent inadvertent introduction of microbes into the blood sample.
  • the haemolysis stabilising composition may also be provided as a dry powder, except for the red cell membrane solubilisation agent which is a solution, although this component is a very small liquid amount which would be absorbed by the other solid components.
  • the haemolysis stabilising composition may also be coated on the surface of plastic or glass such as inside a blood sample container such as a vial, and which would dissolve on the addition of water before use.
  • a haemolysis stabilising composition comprising:
  • a pH of the composition is substantially in the range 6.5 to 7.45;
  • an osmolarity of the composition is of between about 40 to about 80 mOsmol/kg
  • haemolysis stabilisation composition releases and stabilises the cellular haemoglobins, comprising HblAc, to achieve an extracellular haemoglobin to HbAlc ratio that is at least 95 % of the haemoglobin to HbAlc ratio of freshly collected red blood cells.
  • the extracellular HblAc level may be at least 98 to 99.99 % of the HblAc level in a freshly collected whole blood sample over a time period of approximately 120 hours.
  • a method of determining the HbAlc content in a blood sample from a patient comprising the steps of:
  • step (b) collecting the whole blood sample from the patient and transferring it into the receptacle of the whole blood sample container from step (a);
  • step (c) mixing the collected whole blood sample from step (b) above with the haemolysis stabilising composition in the receptacle;
  • step (d) loading the mixture from step (c) above on an analytical instrument to measure the HbAlc level.
  • whole blood typically means unmodified (not separated), arterial or venous blood, such as that drawn from a subject. But the term is also intended to encompass any blood drawn from a subject that has not been separated into component parts by means such as centrifugation.
  • the whole blood sample may be human blood or a whole blood sample of non-human animal origin such as cow, pig, sheep, mouse, dog, monkey, rabbit, chicken or the like. Provided the analytical instrument is calibrated to analyse the particular whole blood sample.
  • a whole blood sample may be taken by a finger prick into a capillary tube, typically about 10 uL, and then transferred in a vial containing about 2 ml of the haemolysis stabilising composition that lyses the red cells and stabilizes the haemoglobin and HbAlc.
  • the blood is "washed" out of the capillary tube by gentle mixing and dispersal in a solution of the haemolysis stabilising composition.
  • the vial is then sent to a laboratory for the sample to be analysed.
  • the whole blood sample container with the whole blood sample and used capillary tube is placed directly on the analytical instrument for analysis.
  • the analytical instruments that the haemolysis stabilising composition may be used on include laboratory based analytical instruments.
  • the analytical instrument may be the TOSOH Bioscience G7 or G8 HPLC.
  • a blood sample container comprising:
  • the blood sample container could be manufactured out of a rigid material capable of being sterilised.
  • the container materials may be inert with respect to the blood and haemolysis stabilisation composition, examples including glass or plastic.
  • the container may also be configured to be airtight. Examples include Vacutainer ® tubes that may contain additives or preservatives for stabilising the blood sample.
  • haemolysis stabilisation compositions and methods of use are now described by reference to a specific example.
  • a haemolysis composition was prepared by combining the components as set out in the below Table 1 below.
  • the concentration of Triton X-100 is based on an average molecular weight of 625.
  • Osmolality (mOsmol/kg) 62 40 to 80
  • the osmolality is too high, it may be adjusted to the target result by adding extra water.
  • HSS haemolysis stabilising solution
  • Example 1 The haemolysis stabilising solution (HSS) as prepared in Example 1 above was mixed with a sample of human blood.
  • the stability of HblAc was demonstrated by analysing HbAlc levels of a HSS-blood sample mixture over a 120 hour period (5 days). This result was obtained using a Tosoh Bioscience G8 analytical instrument.
  • the HbAlc levels are shown in Table 3 below and represented in Figure 1.
  • HSS of the present invention enables accurate measurement of HblAc levels up to 5 days (depending upon ambient temperature) after blood sample collection and is therefore useful as a clinical laboratory test and in the pharmaceutical field.
  • the embodiments described above may also be said broadly to consist in the parts, elements and features referred to or indicated in the specification of the application, individually or collectively, and any or all combinations of any two or more said parts, elements or features.
  • haemolysis stabilising composition has been described by way of example only and it should be appreciated that modifications and additions may be made thereto without departing from the scope of the present invention as defined in the appended claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des compositions de stabilisation d'hémolyse et des procédés d'utilisation dans l'industrie médicale pour l'analyse d'échantillons de sang total provenant de patients. Les compositions contiennent une combinaison d'agents comprenant au moins un agent de solubilisation de membrane de globule rouge, au moins un agent de chélation, au moins un agent de liaison à la méthémoglobine, au moins un agent tampon de pH, au moins un agent anticoagulant et au moins un agent de stabilisation de l'hémoglobine qui contribue à améliorer la stabilité de l'hémoglobine pendant le transport à des températures ambiantes et la facilité d'utilisation pour la collecte et l'analyse des échantillons de sang total prélevés.
PCT/NZ2016/050077 2015-05-15 2016-05-13 Composition de stabilisation d'hémolyse WO2016186521A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ708194 2015-05-15
NZ70819415 2015-05-15

Publications (1)

Publication Number Publication Date
WO2016186521A1 true WO2016186521A1 (fr) 2016-11-24

Family

ID=57320950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2016/050077 WO2016186521A1 (fr) 2015-05-15 2016-05-13 Composition de stabilisation d'hémolyse

Country Status (1)

Country Link
WO (1) WO2016186521A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111551410A (zh) * 2020-05-21 2020-08-18 四川赛尔医学检验有限公司 一种糖化血红蛋白质控物及其制备方法
US20210345609A1 (en) * 2020-05-11 2021-11-11 Nanjing Jixing Biotechnology Development Co., Ltd. Aminocarboxylic acid chelating agent with antifungal activity and synergistic use thereof with other sterilants
CN113959807A (zh) * 2021-10-26 2022-01-21 上海瀚诺威生物科技有限公司 一种糖化血红蛋白校准质控品的制备方法
CN116625777A (zh) * 2023-07-21 2023-08-22 山东新华医疗器械股份有限公司 低水平冻干态糖化血红蛋白质控品及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158866A1 (en) * 2004-01-16 2005-07-21 Xie Zongcen C. Methods and systems for point of care bodily fluid analysis
US20060228803A1 (en) * 2005-04-08 2006-10-12 Ryan Wayne L Cellular controls for glycated hemoglobin Hb A1c
US20080233605A1 (en) * 2003-11-19 2008-09-25 Daichi Pure Chemicals Co., Ltd. Method of Assaying Glycated Protein
US20130171676A1 (en) * 2010-08-11 2013-07-04 Kyowa Medex Co., Ltd. Method for measuring glycated hemoglobin
US20150004635A1 (en) * 2012-02-09 2015-01-01 Kyowa Medex Co., Ltd. Method for suppressing the effects of ascorbic acid
US20150132786A1 (en) * 2011-06-17 2015-05-14 Haruyo Soya Method for measuring glycosylated hemoglobin, measurement reagent, and measurement kit

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080233605A1 (en) * 2003-11-19 2008-09-25 Daichi Pure Chemicals Co., Ltd. Method of Assaying Glycated Protein
US20050158866A1 (en) * 2004-01-16 2005-07-21 Xie Zongcen C. Methods and systems for point of care bodily fluid analysis
US20060228803A1 (en) * 2005-04-08 2006-10-12 Ryan Wayne L Cellular controls for glycated hemoglobin Hb A1c
US20130171676A1 (en) * 2010-08-11 2013-07-04 Kyowa Medex Co., Ltd. Method for measuring glycated hemoglobin
US20150132786A1 (en) * 2011-06-17 2015-05-14 Haruyo Soya Method for measuring glycosylated hemoglobin, measurement reagent, and measurement kit
US20150004635A1 (en) * 2012-02-09 2015-01-01 Kyowa Medex Co., Ltd. Method for suppressing the effects of ascorbic acid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KELTANEN, T. ET AL.: "Measuring postmortem glycated hemoglobin - A comparison of three methods", LEGAL MEDICINE., vol. 15, no. 2, 2013, pages 72 - 78, XP028976116 *
ROHLFING, C.L. ET AL.: "Effects of Whole Blood Storage on Hemoglobin Alc Measurements with Five Current Assay Methods", DIABETES TECHNOLOGY AND THERAPEUTICS., vol. 14, no. 3, 2012, pages 271 - 275, XP055331228 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210345609A1 (en) * 2020-05-11 2021-11-11 Nanjing Jixing Biotechnology Development Co., Ltd. Aminocarboxylic acid chelating agent with antifungal activity and synergistic use thereof with other sterilants
CN111551410A (zh) * 2020-05-21 2020-08-18 四川赛尔医学检验有限公司 一种糖化血红蛋白质控物及其制备方法
CN113959807A (zh) * 2021-10-26 2022-01-21 上海瀚诺威生物科技有限公司 一种糖化血红蛋白校准质控品的制备方法
CN116625777A (zh) * 2023-07-21 2023-08-22 山东新华医疗器械股份有限公司 低水平冻干态糖化血红蛋白质控品及其制备方法
CN116625777B (zh) * 2023-07-21 2023-10-13 山东新华医疗器械股份有限公司 低水平冻干态糖化血红蛋白质控品及其制备方法

Similar Documents

Publication Publication Date Title
Gaweda Markers of iron status in chronic kidney disease
WO2016186521A1 (fr) Composition de stabilisation d&#39;hémolyse
CN105548560A (zh) 血清白蛋白检测试剂和血清白蛋白检测方法
CN108287245A (zh) 测定糖化血红蛋白的试剂盒及其制备方法
TWI842742B (zh) 模擬糞便、及使用其之糞便潛血檢查的精確度管理方法
JP4755802B2 (ja) クレアチニン・センサーの校正
CN106645665A (zh) 一种凝血酶时间检测试剂
Lippi et al. Evaluation of different mixing procedures for K2 EDTA primary samples on hematological testing
CN102620950B (zh) 血小板护维剂
CN106645751B (zh) 一种纤维蛋白原含量检测试剂盒
JP2018025486A (ja) 血清アルブミンの酸化型及び還元型の分別測定法
CN107561296A (zh) 一种测定凝血酶时间（tt）的试剂盒
JP2008058033A (ja) カルシウム濃度測定試薬および測定方法
CN112730833A (zh) 一种免疫透射比浊法的铜蓝蛋白测定试剂盒
JP4163056B2 (ja) 血中インスリン濃度測定用添加剤組成物及びそれを含む採血管
Cichocka et al. Is HbA1c the only choice? Alternative biomarkers for glycaemic control assessment
US11906532B2 (en) Hemostasis measurement device quality control formulations
JP6605990B2 (ja) 血液分析装置の精度管理用管理物質及びその製造方法
JP7376361B2 (ja) 免疫調節マクロライドのための安定な配合物
JP3965433B2 (ja) 試料中の総蛋白質測定試薬及び測定方法
JPWO2010101206A1 (ja) 管理試料の安定化剤、当該安定化剤を含有する管理試料、及び、当該管理試料を含む測定用キット
WO2024140721A1 (fr) Réactif de détection d&#39;hémoglobine gliquée, procédé de détection et utilisation
WO2024204342A1 (fr) Solution et procédé permettant de transporter ou de stocker un échantillon de fluide corporel
JP5259226B2 (ja) 管理試料調製用試薬
JP4231721B2 (ja) 補体価測定用試薬及びそれを用いた補体価測定値の安定化方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16796822

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16796822

Country of ref document: EP

Kind code of ref document: A1